Alembic Pharma Q1 Results: Net profit rises 15%, revenue up 10%
Published on 05/08/2025 01:32 PM
Alembic Pharma Q1 Results: Net profit rises 15%, revenue up 10%Its Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) grew by 19% to ₹282 crore, from ₹237 crore in the corresponding quarter last year. EBITDA margin improved to 16.5% from 15.2% on a year-on-year basis.By CNBCTV18.com August 5, 2025, 1:32:35 PM IST (Updated)1 Min ReadAlembic Pharmaceuticals on Tuesday, August 5, announced its June quarter results, in which its net profit increased by 15% to ₹154 crore. This when compared to ₹135 crore in the same quarter last year (year-on-year).
Revenue rose by 10% to ₹1,711 crore, as against ₹1,562 crore in the year-ago period.
Its Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) grew by 19% to ₹282 crore, from ₹237 crore in the corresponding quarter last year.
EBITDA margin improved to 16.5% from 15.2% on a year-on-year basis.
Following the earnings announcement, shares of Alembic Pharmaceuticals Ltd. are trading flat at ₹968.75. The stock is down 8% on a year-to-date basis.Continue ReadingFirst Published: Aug 5, 2025 1:31 PM ISTCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsAlembic PharmaAlembic Pharmaceuticals